Chardan Capital Maintains Buy on Passage Bio, Lowers Price Target to $6
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $7 to $6.
Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $7 to $6.